Products
Comprehensive catalog of pharmaceutical solutions. Browse categories and send inquiries directly.
All Products (882)
| Molecule | Drug Class / Mechanism | Oncology Type | Inquiry | |
|---|---|---|---|---|
Lifirafenib |
BRAF / MEK Inhibitor | Solid Tumour | ||
|
Molecule
Lifirafenib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
BRAF / MEK Inhibitor |
||||
Linifanib |
Multi-Kinase / Anti-Angiogenic Inhibitor | Solid Tumour | ||
|
Molecule
Linifanib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
Multi-Kinase / Anti-Angiogenic Inhibitor |
||||
Linperlisib |
PI3K Inhibitor | Both (Solid & Hematologic) | ||
|
Molecule
Linperlisib
Therapeutic Category
Targeted Therapy
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
PI3K Inhibitor |
||||
Linvoseltamab |
Bispecific T-Cell Engager | Both (Solid & Hematologic) | ||
|
Molecule
Linvoseltamab
Therapeutic Category
Immunotherapy (Bispecific Antibody)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Bispecific T-Cell Engager |
||||
Lirafugratinib |
FGFR Inhibitor | Solid Tumour | ||
|
Molecule
Lirafugratinib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
FGFR Inhibitor |
||||
Lisaftoclax |
BCL-2 Inhibitor | Hematologic | ||
|
Molecule
Lisaftoclax
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic
Drug Class / Mechanism
BCL-2 Inhibitor |
||||
Loncastuximab Tesirine |
ADC | Hematologic | ||
|
Molecule
Loncastuximab Tesirine
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Hematologic
Drug Class / Mechanism
ADC |
||||
LY3410738 (IDH1/2 Inhibitor) |
IDH1/2 Inhibitor | Hematologic (AML) | ||
|
Molecule
LY3410738 (IDH1/2 Inhibitor)
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (AML)
Drug Class / Mechanism
IDH1/2 Inhibitor |
||||
Margetuximab |
Anti-HER2 Agent | Solid Tumour (Breast/Gastric) | ||
|
Molecule
Margetuximab
Therapeutic Category
Targeted Therapy (Antibody / ADC)
Oncology Type
Solid Tumour (Breast/Gastric)
Drug Class / Mechanism
Anti-HER2 Agent |
||||
Marizomib |
Proteasome Inhibitor | Hematologic (Multiple Myeloma) | ||
|
Molecule
Marizomib
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Multiple Myeloma)
Drug Class / Mechanism
Proteasome Inhibitor |
||||
Masitinib |
Multi-Kinase / Anti-Angiogenic Inhibitor | Solid Tumour | ||
|
Molecule
Masitinib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
Multi-Kinase / Anti-Angiogenic Inhibitor |
||||
Masofaniten |
Androgen Receptor Degrader (PROTAC) | Solid Tumour (Prostate) | ||
|
Molecule
Masofaniten
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour (Prostate)
Drug Class / Mechanism
Androgen Receptor Degrader (PROTAC) |
||||
LifirafenibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
BRAF / MEK Inhibitor |
|
LinifanibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
Multi-Kinase / Anti-Angiogenic Inhibitor |
|
LinperlisibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
PI3K Inhibitor |
|
LinvoseltamabImmunotherapy (Bispecific Antibody) |
|
|
Therapeutic Category
Immunotherapy (Bispecific Antibody)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Bispecific T-Cell Engager |
|
LirafugratinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
FGFR Inhibitor |
|
LisaftoclaxTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic
Drug Class / Mechanism
BCL-2 Inhibitor |
|
Loncastuximab TesirineTargeted Therapy (Antibody-Drug Conjugate) |
|
|
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Hematologic
Drug Class / Mechanism
ADC |
|
LY3410738 (IDH1/2 Inhibitor)Targeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (AML)
Drug Class / Mechanism
IDH1/2 Inhibitor |
|
MargetuximabTargeted Therapy (Antibody / ADC) |
|
|
Therapeutic Category
Targeted Therapy (Antibody / ADC)
Oncology Type
Solid Tumour (Breast/Gastric)
Drug Class / Mechanism
Anti-HER2 Agent |
|
MarizomibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Multiple Myeloma)
Drug Class / Mechanism
Proteasome Inhibitor |
|
MasitinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
Multi-Kinase / Anti-Angiogenic Inhibitor |
|
MasofanitenTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour (Prostate)
Drug Class / Mechanism
Androgen Receptor Degrader (PROTAC) |
|